AZR: Coastlands Capital exits Azora stake, now below 5% holding
Coastlands Capital exited AZR: 655,975 shares (4.99%) now below 5% stake threshold after 13G/A exit filing, Nov 2, 2026.
What this filing says
Coastlands Capital reports it no longer owns more than 5% of Azora Therapeutics common stock, so this amendment is an exit filing. The filing reports 655,975 shares, or 4.99% of the class, held by Coastlands Capital Partners LP as of the November 2, 2026 event date. For a shareholder, this is a disclosure that a reporting holder has dropped below the 5% threshold, not a stated buy or sell decision by the company.
Key figures
- Shares beneficially owned
- 655,975 shares
- Percent of class
- 4.99%
- Shares outstanding used in calculation
- 12,878,129 shares
- Date of event
- 11/02/2026
Negative for shareholders
- The filing reports a reduction in a holder's stake below the 5% reporting threshold, which removes a reporting shareholder from the public filings.
Written by Quantisnow AI from this filing. Not financial advice.
Key terms
- Schedule 13G:
- A short SEC filing that passive investors file to disclose owning more than 5% of a company's shares.
- Pre-funded warrants:
- Options to buy common stock for a very small price, often used in place of shares so an investor can avoid crossing an ownership limit.
- Beneficial ownership limitation:
- A cap written into a warrant that stops the holder from exercising it if that would push ownership above a set percentage.
- Exit filing:
- A final amendment stating that the filer no longer owns more than 5% and will stop reporting on the stake.
FAQ
How much of Azora Therapeutics does Coastlands Capital still hold?
The filing reports 655,975 shares, or 4.99% of the class, beneficially owned by Coastlands Capital Partners LP and Coastlands Capital LP.
Why is this filing an exit filing?
The filing states that the reporting persons no longer beneficially own more than 5 percent of any class of Azora's securities.
Does the holding include warrants?
Yes, the reported shares include common stock issuable on exercise of pre-funded warrants, subject to a 4.99% beneficial ownership limit.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2018
Follow AZR and get a push notification the moment its next story breaks.